CAS Medical Systems, Inc. Announces FDA 510(k) Clearance Expanding Labeling for FORE-SIGHT Cerebral Oximeter

FORE-SIGHT Now Indicated for Use On Neonates Weighing Less Than 2.5kg

CAS Medical Systems, Inc. (Nasdaq:CASM) announced today a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the labeling for its FORE-SIGHT(r) Cerebral Oximeter. The new labeling allows FORE-SIGHT to be used on all patients, including those weighing less than 2.5 Kilograms (kg).

The FORE-SIGHT Cerebral Oximeter is a Near Infra-Red Spectroscopy (NIRS) based device that non-invasively and continuously detects oxygen saturation changes in brain tissue, allowing clinicians to quickly react to reverse potentially harmful events before they become critical. FORE-SIGHT is the first and only device on the market today that provides a non-trend, absolute measure of cerebral tissue oxygen saturation for all patient populations regardless of age and weight.

Strategic Diagnostics Awarded Patent For Use of Bacteriophages in Microbiological Assays and Processes

SDI (Strategic Diagnostics Inc., NASDAQ: SDIX), a leading provider of biotechnology-based products and services for a broad range of food safety, life science and industrial applications, today announced it has been awarded U.S. Patent No. 7,521,201 B2 for using bacteriophages in microbiological assay tests and processes. The invention is a rapid bacterial detection method that reduces or eliminates the growth of undesirable bacteria, resulting in improved test performance.

The invention addresses the problem of how to detect a harmful pathogen among billions of other bacteria present in a test sample. Reducing the growth of competing bacteria in the sample reduces false negative results, while preventing the growth of cross reactive bacteria in the sample reduces false positive results. Together, these benefits reduce the time required to obtain test results while improving the accuracy of test methods.

LabCorp Enters Definitive Agreement to Acquire Monogram Biosciences, Inc.

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) and Monogram Biosciences, Inc. (NASDAQ: MGRM) today announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55 per share for an implied total equity value of approximately $106.7 million, or a total enterprise value of approximately $155 million at March 31, 2009, including net indebtedness.

“The transaction announced today is a significant step in the execution of LabCorp’s strategy of leadership in personalized medicine,” said David P. King, Chairman and Chief Executive Officer of LabCorp.

Amorfix Licenses Novel Theranostic Platform - ProMIS(TM) - For Predicting Protein Misfolding

- Platform Predicts Novel Therapeutic and Diagnostic Targets -

Amorfix Life Sciences (TSX:AMF), a company focused on treatments and diagnostics for misfolded protein diseases announces it has licensed the exclusive rights to the ProMIS(TM) target identification technology from the University of British Columbia (UBC), to predict novel Disease Specific Epitopes (DSE) on the molecular surface of misfolded proteins.

"The ProMIS(TM) target identification technology is a breakthrough method to model virtually any protein and predict how it will misfold," said Dr. George Adams, CEO of Amorfix. "PROMIS(TM) has already been used to identify potential DSE's on three known target proteins likely to be misfolded in cancer and the development of novel immunotherapeutics and companion diagnostics for these diseases has begun."